iCell Cardiomyocytes²

Speed up cardiac research with FUJIFILM CDI’s iCell^® Cardiomyocytes². These cells are the enhanced version of the industry standard CDI iCell Cardiomyocytes, designed for stability, versatile use, and biological relevance.

Derived from induced pluripotent stem cells (iPSCs), CDI cardiomyocytes deliver reliable insights into cardiac function in health and disease. With rapid recovery from cryopreservation and minimal handling required, you can depend on iCell Cardiomyocytes² to drive your cardiac research forward.

• Quick recovery Optimized for rapid post-thaw recovery, iCell Cardiomyocytes² move from cryopreservation to assay-ready in 4 days.
• Stable populations Transcriptional and phenotypic stability and >95% cardiomyocyte purity ensures reproducible results across every batch of CDI cardiomyocytes.
• Demonstrated excellence The CDI iCell Cardiomyocytes platform has powered an industry-leading number of peer-reviewed publications.
• Native functionality With biochemical, electrophysiological, and contractile responses closely reflecting those of primary cardiomyocytes, get biologically relevant results with iCell Cardiomyocytes².
• Versatile applications From target identification to drug-induced arrhythmias, iCell Cardiomyocytes² fuel diverse research—always supported by CDI’s optimized protocols and technical expertise.